Afecta has assembled a portfolio of new and effective pharmaceutical products. Because general "proof-of-principle" has already been established in previous application, human usage or extensive pre-clinical testing of our new therapeutics will have shortened timelines to market. With our technology platform and product development strategies, Afecta also has created a powerful drug development engine that will help ensure a robust pipeline of new drug products well into the future.

Afecta's current lead products are:

AFX-929 is a new drug for treatment of Alzheimer's disease in addition to being a very effective treatment of symptoms of cognitive impairment. It also has activity in ameliorating the disease process itself.

AFX-221 is a new non-stimulant that targets multiple neurotransmitters and is being developed for treatment for AD/HD and Tourette syndrome. It is designed to be a low dose, once a day medication.

AFX-9154 is a protein-based therapeutic that causes tumor cells to become more immunogenic and activates the body's own immune system to kill tumor cells. It is currently in clinical trials for treatment of leukemia.

AFX-9901 is derived from a natural compound and has potent tumorcidal and anti-angiogenic properties. In pilot human studies it demonstrated efficacy in a variety of solid tumors and had minimal side effects.

In addition to these products, Afecta has a number of late pre-clinical stage drugs in various stages of development. Because each is based on existing well-known compounds they are likely to be ready for final clinical testing within four years.